
Cambridge English Qualifications Digital: Empowering Schools, Universities, and International Students with a Smarter Way to Certify English Proficiency
SINGAPORE, May 26, 2025 /PRNewswire/ -- In today's global academic landscape, the ability to demonstrate English proficiency with speed, flexibility, and confidence is more important than ever. Cambridge English Qualifications Digital, developed by Cambridge English (part of the University of Cambridge), offers a modern, computer-based exam experience that meets the evolving needs of educational institutions and international learners.
Designed for students from A2 Key to C2 Proficiency, these digital qualifications provide the same trusted content and rigorous standards as traditional paper-based exams, while introducing a range of digital enhancements that make the testing process more accessible, efficient, and student-friendly. Whether preparing for university admission, applying for international study programs, or meeting graduation requirements, Cambridge English Qualifications Digital helps learners showcase their language skills with confidence and credibility.
For schools and universities, the digital format offers greater scheduling flexibility, faster results, and a streamlined exam experience that aligns with the digital learning environments students are already familiar with. For international students, it provides a globally recognised certification that supports academic mobility and opens doors to higher education and career opportunities worldwide.
A Seamless Fit for Modern Education
Cambridge English Qualifications Digital are designed to integrate effortlessly into the academic calendar and digital infrastructure of schools and universities. With more exam dates and locations available, institutions can offer students greater choice and convenience, reducing scheduling conflicts and administrative overhead.
The digital format also supports faster turnaround times for results, enabling institutions to make timely decisions on admissions, course placements, and graduation eligibility. This is especially valuable for international students who often face tight deadlines for visa applications, scholarship submissions, or university enrolment.
"The digital exams have made it easier for us to plan around our academic calendar. Students appreciate the flexibility, and we appreciate the efficiency," says the Director of Language Programs at a leading European university.
Designed for Digital Natives
Today's students are digital natives. They learn, communicate, and collaborate in digital environments—and they expect their assessments to reflect that reality. Cambridge English Qualifications Digital are built with this in mind, offering a user-friendly interface and intuitive tools that help students perform at their best.
Key Features:
These features not only enhance the candidate experience but also reflect the digital communication skills students will need in academic and professional settings.
Trusted by Educators, Preferred by Students
Cambridge English Qualifications Digital are already being used by schools and universities around the world, with overwhelmingly positive feedback from both educators and learners.
"It's all advantages for candidates. They like doing it. My students keep coming back to do more exams," says Alex, a teacher from Spain.
"The digital format really helps students feel more confident. They're used to typing and navigating screens—it's second nature to them," adds Selin, a teacher in Turkey.
For educators, the digital exams offer a reliable and scalable solution that aligns with modern teaching practices. For students, they provide a familiar and empowering way to demonstrate their language skills.
No Need to Change How You Teach
One of the most reassuring aspects for schools and universities is that the digital exams test the same knowledge and skills as the paper-based versions. This means there's no need to overhaul teaching methods or materials. Teachers can continue using their existing coursebooks and lesson plans while integrating digital practice tools to help students become familiar with the exam format.
Cambridge English also provides a wide range of free and premium preparation resources to support both classroom instruction and independent study.
Powerful Digital Preparation Tools
To help students prepare effectively, Cambridge English offers a suite of digital tools that mirror the exam experience and build confidence:
"Test & Train is really useful because students can practise on the go. If they have it on their phone, they can even be sitting on the bus or the metro and do a few exercises," says Sarah, an Examination Centre Deputy Director.
These tools not only improve exam readiness but also support broader language development goals.
Supporting International Students
For international students, Cambridge English Qualifications Digital offer a fast, flexible, and globally recognised way to prove English proficiency. Whether applying to universities in the UK, Australia, Canada, or beyond, these qualifications are accepted by thousands of institutions worldwide.
The digital format also helps reduce logistical barriers. Students can choose from a wider range of test dates and locations, and receive their results more quickly - making it easier to meet application deadlines and visa requirements.
"Having access to a digital exam meant I could take the test in my home country and still meet my university's deadline. It made the whole process much less stressful," says Amina, an international student from Morocco.
A Commitment to Quality and Innovation
As part of the University of Cambridge, Cambridge English is committed to maintaining the highest standards of academic integrity, fairness, and innovation. The digital exams are developed using cutting-edge research in language assessment and educational technology, ensuring they remain valid, reliable, and globally recognised.
Hybrid marking has also been introduced for the Writing component at B1 and B2 levels, combining human expertise with digital efficiency to deliver accurate and timely results.
Ready to Bring Digital Exams to Your Institution?
Whether you're a school administrator, university admissions officer, or international student advisor, Cambridge English Qualifications Digital offer a smarter, faster, and more flexible way to support your learners' success.
Visit cambridgeenglish.org/digital to:
************************************************************
About Cambridge English
Cambridge English is the producer and proud co-owner of IELTS, the world's leading English test for migration and higher education. We help millions of people learn English and prove their skills to the world.
Part of the University of Cambridge, we provide the world's leading range of qualifications and tests for learners and teachers of English. For us, learning English is more than just exams and grades. It's about having the confidence to communicate and access a lifetime of enriching experiences and opportunities.
Whether you're planning to live, work or study in your own country or abroad, we can give you the English language skills to succeed. We provide the world's leading range of qualifications and tests for learners and teachers of English. Globally recognised by more than 25,000 leading universities, employers and governments, our research-based assessments are a mark of excellence that open doors.
Our work is supported around the world by a network of 2,800 exam centres, over 50,000 schools and tens of thousands of examiners, teachers, education experts and publishers. Working together, we inspire learners to go further.
With the right support, learning a language is an exhilarating journey. We're with you every step of the way.
What we believe – To learn English is to enjoy and experience a language that opens up opportunities across the world.
What we offer – Together with teachers and our partners, we're here to engage and inspire millions of people throughout their entire English language learning journey, helping them confidently prove their skills to the world.
How we do things and the impact we have – As part of a university with global reputation for academic excellence, we create insights derived from deep research, expertise and experiences. This ensures our unique approach meets the real-life needs of learners through inclusive and accessible products and services.
The global role of English – As a global language, English unlocks a lifetime of experiences, and – because language is at the heart of being human – we help people everywhere connect, communicate and come closer together.
- END -
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
23 minutes ago
- Korea Herald
Exploring Growatt's Latest PV and Energy Storage Innovations at SNEC 2025
BERLIN, June 16, 2025 /PRNewswire/ -- Growatt showcased its latest solar and energy storage innovations at SNEC PV Power Expo 2025 in Shanghai, from June 11–13. The exhibit featured smart, scalable solutions for residential, C&I, and balcony solar, highlighting Growatt's commitment to empowering global energy independence. Key highlights included next-gen hybrid inverters, plug-and-play storage systems, and high-performance utility-scale solutions. Residential Solar and Energy Storage Solutions: Smarter, Safer, and More Scalable Ranked as the Global Top 2 Residential Inverter Supplier, Growatt continues to set benchmarks in smart home energy with solutions that are more intelligent, secure, and adaptable to different household needs. Leading the residential showcase was the NEXA 2000, an innovative balcony energy storage system designed for urban households and compact spaces. This plug-and-play solution supports up to 2600W PV input, 4 MPPTs, and 20A string current, making it ideal for 650W+ high-power modules. Its modular battery design, expandable up to 8kWh, enables flexible energy storage. The system also features AI-powered smart scheduling, Time-of-Use (ToU) optimization, and an off-grid mode for backup power during outages. In addition, Growatt also featured a wide range of hybrid and off-grid residential solutions that empowers homeowners to achieve energy independence: All residential products integrate with Growatt's smart platforms—ShinePhone, ShineServer, and OSS—to provide real-time monitoring, intelligent energy scheduling, and remote diagnostics. Commercial, Industrial & Utility Solutions: Powering Business at Every Scale Growatt, ranked among the Top 5 global commercial inverter suppliers, continues to empower EPCs, developers, and enterprises with scalable and intelligent energy solutions. At SNEC 2025, the company unveiled a full spectrum of innovations spanning commercial rooftops to utility-scale ground mounts. For commercial and industrial (C&I) applications, Growatt showcased high-performance hybrid and on-grid inverters: From commercial rooftops to utility farms, Growatt's advanced C&I and utility products deliver the efficiency, flexibility, and intelligence needed to future-proof large-scale solar projects. Driving Innovation with Global Partners With over a decade of experience and installations in 180+ countries, Growatt has become one of the most trusted names in solar inverter and energy storage technology. This year's SNEC presence was not just a product showcase, but a reaffirmation of the brand's mission to democratize clean energy through accessible and scalable solutions. "We're thrilled to return to SNEC 2025 and connect with our global partners," said Lisa Zhang, Vice President at Growatt. "Our innovations this year—from balcony PV systems to commercial hybrid energy storage—are designed to meet the diverse and evolving needs of customers around the world." About Growatt Founded in 2011, Growatt is a globally recognized provider of distributed solar and energy storage solutions, offering PV inverters, battery storage systems, EV chargers, and smart energy management platforms. With a strong R&D team and a presence in over 180 countries, Growatt continues to lead in technology innovation and customer satisfaction, empowering a greener, more sustainable future.


Korea Herald
2 hours ago
- Korea Herald
Tencent Cloud Commits to Support European Companies' Global Competitiveness and Realise AI Ambitions
PARIS, June 16, 2025 /PRNewswire/ -- At Viva Technology 2025, Europe's largest technology event, Tencent Cloud highlighted the accelerating shift among enterprises toward connected platforms and multi-cloud strategies, key enablers for unlocking the full potential of AI and driving sustainable innovation and global competitiveness. Speaking on the panel "AI Beyond Scale: Building competitive and sustainable ecosystems", Dowson Tong, Senior Executive Vice President of Tencent and CEO of its Cloud & Smart Industries Group emphasized that the future of AI is advancing beyond scale, driving deeper integration into industries and everyday life, transforming how businesses operate and enhancing user experiences. "The next phase of AI promises more than just operational efficiency," Tong said. "To unlock its full potential and remain globally competitive, European enterprises must adopt an ecosystem-driven approach. By drawing on deep ecosystem expertise, businesses can accelerate time-to-value, deploying and building AI components from customer service agents and knowledge engines to industry-specific AI solutions. A modular, multi-cloud strategy further supports this by enabling scalable innovation while ensuring operational efficiency, all built on secure, scalable digital infrastructure." With AI reshaping business models, European organizations need resilient, flexible, and diverse cloud infrastructure. According to Gartner, 90% of organizations will adopt a hybrid cloud approach by 2027. Tencent Cloud supports this shift with future–ready AI and cloud solutions for Europe, along with seamless links to high–growth regions, helping businesses turn AI potential into real–world impact and sustain a competitive edge. In conjunction with the event, Orange is rolling out a soft launch of the upgraded Max It super app, pacing its way to delivering a next-level, simplified lifestyle experience available for its 160m mobile customers across the Middle East and Africa (MEA). Starting June 2025, the new upgrade will empower users to shop, explore new services and offers from their favourite brands, make utility payments, and book movies and event tickets all through a unified mini-app platform on a single mobile interface. Orange super app integrates Tencent Mini app solution (TCMPP), and is enhanced by Tencent Cloud real-time chat solution, the app also offers a new holistic experience enabling users to chat, transfer funds, and engage within the app, unlike any other telco or e-commerce app currently in the market. The latest upgrade now features over 20 new mini apps across utilities, e-commerce, and retail. This ecosystem will grow rapidly, as the platform opens up to more than 100,000 partners to develop and onboard mini apps ahead of its official full launch in the near future. Achieving real-world impact with AI Beyond boosting global competitiveness for enterprises, Tencent's AI-powered advancements in healthcare are putting effective new tools in the hands of healthcare and medical experts, while also empowering patients to take greater control of their health. Speaking at "The Intelligent Ally: How Is AI Reshaping Medical Practice?" panel session, Dr. Alex Ng, President of Tencent Healthcare, shared, "Tencent is helping transform the global healthcare landscape by bridging the gap between international pharmaceutical companies and local healthcare systems through advanced digital platforms." From a Hunyuan-powered medical consultation service being deployed at 10,000 medical institutions in China, to AI-powered medical imaging with over 10 million scans analyzed, Tencent Healthcare's AI-powered solutions are holistic in addressing early detection, operational efficiency, and patient trust. Tencent Cloud also successfully supported French multinational pharmaceutical giant Sanofi expand their operations in China by building a centralized data lake and unified digital platform, streamlining operations across business units, empowering the organizations to expand and scale in the Chinese market. Advancing European Enterprise Growth at Global Scale From building immersive gaming environments with Cathedral Studios, to advancing smart driving with Bosch and transforming in-car entertainment with Mercedes-Benz and Electronic Arts, Tencent Cloud's expertise in gaming, digital content, payments, cloud and platform technologies continues to support the aspirations of Europe's leading brands. Leveraging a track record of collaborating with over 11,000 global and local partners, offering more than 400 solutions across 30 industries, used by more than 10,000 enterprises in 200 markets and regions worldwide, Tencent continues to grow this network to help businesses innovate responsibly and sustainably in the AI era. About Tencent Cloud Tencent Cloud, one of the world's leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel and transportation.

Korea Herald
6 hours ago
- Korea Herald
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
INCHEON, South Korea, June 16, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA). [1] With this approval, STEQEYMA now offers all dosage forms and strengths of its reference product, providing flexibility to meet physicians' clinical needs while supporting treatment continuity for patients. In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in adult and pediatric patients 6 years and older with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis. "Managing inflammatory diseases in pediatric patients can be particularly complex," said Hetal Patel, PharmD MBA, Vice President of Medical Affairs at Celltrion USA. "The new dosage form and strength of STEQEYMA allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile." "We are proud to offer a new presentation of STEQEYMA that aligns with the indications of the reference product," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This approval reinforces our commitment to broadening access for all patient populations, including children aged 6 years and older living with chronic inflammatory conditions. As a company with a strong legacy in immunology, we are dedicated to ensuring broader access and flexibility in care for patients of all ages." The FDA approval of STEQEYMA was based on the totality of evidence, including the results from a phase III study in adults with moderate to severe plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. [2], [3] The FDA has granted STEQEYMA full interchangeability with STELARA across all indications of STELARA, following the expiration of exclusivity for the first interchangeable biosimilar on April 30, 2025. Notes to Editors: About STEQEYMA ® (ustekinumab-stba) STEQEYMA ®, formerly known as CT-P43, is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases. It encompasses all indications approved for the STELARA ® reference product, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), ulcerative colitis (UC) in adults, and PsO and PsA in pediatric patients 6 years of age and older. STEQEYMA is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes in 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe and 45mg/0.5mL solution in a single-dose vial. The intravenous infusion is provided as a 130mg/26 mL (5mg/mL) solution in a single-dose vial. INDICATIONS IMPORTANT SAFETY INFORMATION For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), AVTOZMA ® (tocilizumab-anho), STEQEYMA ® (ustekinumab-stba), STOBOCLO ® (denosumab-bmwo), OSENVELT ® (denosumab-bmwo) and OMLYCLO ® (omalizumab-igec), as well as the novel biologic ZYMFENTRA ® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media: LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipate" the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.